ABSTRACT
Background While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen.
Methods In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines (Moderna mRNA-1273 100-μg, Janssen Ad26.COV2.S 5×1010 virus particles, or Pfizer-BioNTech BNT162b2 30-μg; nine combinations). The primary outcomes were safety, reactogenicity, and humoral immunogenicity on study days 15 and 29.
Results 458 individuals were enrolled: 154 received mRNA-1273, 150 received Ad26.CoV2.S, and 154 received BNT162b2 booster vaccines. Reactogenicity was similar to that reported for the primary series. Injection site pain, malaise, headache, and myalgia occurred in more than half the participants. Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2-76-fold) and binding antibody titers (4.6-56-fold) for all combinations; homologous boost increased neutralizing antibody titers 4.2-20-fold whereas heterologous boost increased titers 6.2-76-fold. Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations.
Conclusion Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier.
(Funded by National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04889209)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04889209
Funding Statement
The trial was sponsored and primarily funded by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), under award numbers UM1AI48372, UM1AI148373, UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148574, UM1AI148575, UM1AI148576, UM1AI148684, UM1 AI148689 and with support from the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00050 and NIH Vaccine Research Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Advarra Center for IRB Intelligence
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** The Mix and Match Team members are listed in the Supplemental Appendices
Meagan.Deming{at}som.umaryland.edu, lisa.a.jackson{at}kp.org, angela_branche{at}urmc.rochester.edu, hanae{at}bcm.edu, christina.rostad{at}emory.edu, Judy.Martin{at}chp.edu, cjohnsto{at}uw.edu, rrupp{at}utmb.edu, mark.mulligan{at}nyulangone.org, rebecca.brady{at}cchmc.org, robert.frenck{at}cchmc.org, Martin.Backer{at}nyulangone.org, Angelica.Kottkamp{at}nyulangone.org, tbabu2{at}uw.edu, kumaravel.rajakumar{at}chp.edu, sedupug{at}emory.edu, Ann_Falsey{at}urmc.rochester.edu, cposavad{at}fredhutch.org, JArcher{at}fhi360.org, sonja.crandon{at}nih.gov, seema.nayak{at}nih.gov, dszydlo{at}scharp.org, jzemanek{at}scharp.org, cdomingu{at}fredhutch.org, erbrown{at}fredhutch.org, mehul.s.suthar{at}emory.edu, jmcelrat{at}fredhutch.org, adrian.mcdermott{at}nih.gov, sarah.o%E2%80%99connell{at}nih.gov, david.montefiori{at}duke.edu, amanda.eaton{at}duke.edu, kneuzil{at}som.umaryland.edu, dstep01{at}emory.edu, robertspc{at}nih.gov, jbeigel{at}niaid.nih.gov,
Data Availability
All available data produced in the present work are contained in the manuscript
